Noncontrast CT-Based Deep Learning for Predicting Hematoma Expansion Risk in Patients with Spontaneous Intracerebral Hemorrhage
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQiang Yu
About this trial
Hematoma expansion is an independent predictor of poor prognosis and early neurological deterioration in patients with spontaneous intracerebral hemorrhage. Early identification of high-risk patients and timely targeted medical interventions may provide a crucial opportunity to limit hematoma growth and improve neurological outcomes. This study aims to develop an end-to-end deep learning model based on noncontrast computed tomography images to predict the risk of hematoma expansion in patients with spontaneous intracerebral hemorrhage. This model could serve as a valuable risk stratification tool for patients with hematoma expansion, facilitating targeted treatment and providing clinicians with streamlined decision-making support in emergency situations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Primary, spontaneous (non-traumatic) intracerebral hemorrhage (ICH).
Age ≥ 18 years.
Baseline CT performed within 24 hours of ICH symptom onset or last seen well (LSW).
Follow-up CT within 72 hours.
Disqualifiers
Secondary ICH caused by trauma, vascular anomalies (e.g., aneurysm, cavernous angioma, arteriovenous malformation), brain tumor, or hemorrhagic transformation in brain infarction.
Primary intraventricular hemorrhage (IVH).
Surgical treatment with external ventricular drain placement or craniotomy.
Obvious artifacts observed in CT images.
Trial population
A multicenter retrospective cohort of 2000 patients with spontaneous intracerebral hemorrhage, including 500 cases of hematoma expansion and 1500 cases without hematoma expansion.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Observational study, no interventions involved
Other interventionObservational study, no interventions involved
Treatment groups
2,000 Participants
are divided into 2 treatment groupsGroup A: Hematoma Expansion Group1 intervention
Group B: No Hematoma Expansion Group1 intervention
Trial outcomes
Primary outcomes
1
Prediction of Hematoma Expansion
Proportion of patients with hematoma expansion
Time frame
From the onset of ICH symptoms to 72 hours after baseline CTSponsors and contacts
Click on the lead sponsor to view all of their trials.
Qiang Yu
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Sponsor institution
Xiangya Hospital of Central South University
Collaborator
The First Affiliated Hospital with Nanjing Medical University
Collaborator
Southwest Hospital, China
Collaborator
Liuzhou Workers' Hospital
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: